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Abstract
As PTTG1 (pituitary tumor transforming gene) abundance correlates with adverse outcomes in cancer treatment, we
determined mechanisms underlying this observation by assessing the role of PTTG1 in regulating cell response to anti-
neoplastic drugs. HCT116 cells devoid of PTTG1 (PTTG1
2/2) exhibited enhanced drug sensitivity as assessed by measuring
BrdU incorporation in vitro. Apoptosis, mitosis catastrophe or DNA damage were not detected, but features of senescence
were observed using low doses of doxorubicin and TSA. The number of drug-induced PTTG1
2/2 senescent cells increased
,4 fold as compared to WT PTTG1-replete cells (p,0.001). p21, an important regulator of cell senescence, was induced ,3
fold in HCT116 PTTG1
2/2 cells upon doxorubicin or Trichostatin A treatment. Binding of Sp1, p53 and p300 to the p21
promoter was enhanced in PTTG1
2/2 cells after treatment, suggesting transcriptional regulation of p21. p21 knock down
abrogated the observed senescent effects of these drugs, indicating that PTTG1 likely suppresses p21 to regulate drug-
induced senescence. PTTG1 also regulated SW620 colon cancer cells response to doxorubicin and TSA mediated by p21.
Subcutaneously xenografted PTTG1
2/2 HCT116 cells developed smaller tumors and exhibited enhanced responses to
doxorubicin. PTTG1
2/2 tumor tissue derived from excised tumors exhibited increased doxorubicin-induced senescence. As
senescence is a determinant of cell responses to anti-neoplastic treatments, these findings suggest PTTG1 as a tumor cell
marker to predict anti-neoplastic treatment outcomes.
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Introduction
PTTG1 (pituitary tumor transforming gene), originally isolated
from rat pituitary tumor cells [1], is a securin protein abundantly
expressed in hematopoietic, colorectal, thyroid, lung, breast and
ovarian malignancies [2]. PTTG1 was proposed as a marker of
breast cancer aggressiveness [3,4,5]. Increased PTTG1 expression
correlates with higher colorectal tumor grade, invasion of
surrounding lymph nodes and increased tumor vascularity [6,7].
PTTG1 is a natively unfolded protein [8] which binds to ,700
gene promoters as indicated by ChIP-on-Chip assay [9], and
interacts with ,80 proteins [10]. In addition to its securin function
[11], PTTG1 regulates G2/M phase transition by inhibiting
separase cleavage and aurora kinase A activity [10,12]. PTTG1
also regulates G1/S transition by inducing cyclin D3 and
repressing p21 expression [9]. PTTG1 induces FGF2, stimulates
c-myc expression, inhibits p53 DNA binding and transactivation
and regulates apoptosis [13,14,15,16,17]. PTTG1 over-expression
leads to cell transformation in NIH-3T3 cells, while mouse embryo
fibroblast cells devoid of Pttg are resistant to oncogenic
transformation [9]. Targeted pituitary PTTG over-expression in
Rb
+/2 mice resulted in enhanced cellular activity, increased gland
volume, and higher prevalence of anterior pituitary tumors
[18,19]. Conversely, transgenic pttg deletion abrogated murine
pituitary tumor development [20].
Recent research indicated that PTTG1 regulates cancer cell
growth responses to treatments. Head and neck squamous cell
carcinomas with higher tumor PTTG1 levels exhibit increased
recurrences after radiation, 5-fluorouracil (5-FU) and cisplatinum
treatment [21]. Breast cancers with higher PTTG1 levels are
resistant to tamoxifen and fulvestrant [22]. Reports on gliomas
[23], hepatocellular [24], thyroid [25] and esophageal carcinoma
patients [26] also indicate that higher tumor PTTG1 levels
correlate with adverse clinical outcomes.
PTTG1 has been implicated in mediating oncogene-induced
pituitary tumor senescence [27]. As senescence also determines
cancer therapy outcomes, we examined whether PTTG1 regulates
drug-induced cellular senescence. Here we show here that the
presence of PTTG1 is a determinant of drug-induced senescence.
These findings contribute to understanding the requirement of
PTTG1 for regulation of cancer cell response to anti-neoplastic
drugs.
Materials and Methods
Cell lines and reagents
HCT116 is a human colon carcinoma cell line, expressing wild-
type p53 and PTTG1 genes, and HCT116 p53
2/2 and HCT116
PTTG1
2/2 cell lines were derived using homologous recombina-
tion to knock out p53 or PTTG1 respectively [28,29]. Cells were
cultured in McCoy’s 5A medium containing 15% FBS. SW620
human colon cancer cells were purchased from ATCC (Manassas,
VA) and cultured as recommended. PTTG1 and p300 siRNA
were purchased from Ambion (Austin, TX), p21 and p53 siRNA
from Cell Signaling (Danvers, MA), PTTG antibody from
Invitrogen (Carlsbad, CA), p300 and HDAC1 antibodies from
Santa Cruz (Santa Cruz, CA), p21 antibody from Cell Signaling,
and p53 antibody from CalBioChem (Gibbstown, NJ).
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The BrdU incorporation assay was carried out using Cell
Proliferation ELISA kits from Roche (Indianapolis, IN). Briefly,
2000 HCT116 cells or 3000 SW620 cells were cultured in 96-well
microplates in a final volume of 100 ul culture medium per well,
drugs added and cells incubated for 48 hours. BrdU labeling
solution was added to a final concentration of 10 uM, and cells
incubated for an additional 4 hours at 37uC. The culture medium
was removed and each well washed twice with 250 ul wash
medium containing 10% serum. Cells were fixed and treated with
nucleases working solution for 30 min at 37uC. Incorporated
BrdU was detected using anti-BrdU-POD, Fab fragments and
peroxidase substrate ABTS. Sample absorbance was measured at
405 nm against background control, using a Victor 3 multiwell
plate reader. Inhibition rate was calculated for each well as (A405
control cells - A405 treated cells)/A405 control cells6100% (A405:
OD value at 405 nm)
Senescence detection assay
SA-b-gal enzymatic activity was detected using a Senescence
Cell Staining kit from Sigma-Aldrich (St. Louis, MO). Briefly,
10,000 cells were plated to 12-well plate, incubated at 37uC
overnight and treated with control vehicle or drugs. Forty eight
hours after treatment, cells were washed with PBS (pH 6.0), fixed
overnight, and stained with 5-bromo-4- chloro-3-indolyl-h-D-
galactopyranoside (X-Gal) overnight at 37uC. Ten fields were
randomly selected and cells counted. Senescent rate was calculated
for each field as positive cells/all cells6100%.
Tunel assay
Tunel assay was carried out using in situ cell death detection
kit from Roche. Briefly, 10,000 cells were plated to 12-well plate,
incubated at 37uC overnight and treated with control vehicle or
drugs. Forty eight or 96 hours after treatment, control and drug-
treated cells were trypsinized and resuspended in 100 ul fixation
solution for 30 minutes Cells were permeabilized, washed
and incubated in TUNEL assay mixture at 37uC for 1 hour.
Cells were washed, incubated in 10 ul 16 PBS+0.5 mg/ml
propidium iodide (PI) for 10 min and subject to microscopic
analysis. Ten fields were randomly selected and cells counted.
Apoptotic rate was calculated for each field as positive cells/all
cells6100%.
Western blot
Protein extracts were resolved by Nupage 4–12% Bis-Tris Gel
(Invitrogen), samples electro-blotted onto PVDF membrane
(Invitrogen), and membranes blocked and incubated with primary
antibody. Donkey anti-rabbit or anti-mouse (GE Healthcare, NJ)
antibodies were conjugated to horseradish peroxide to reveal
immunocomplexes by enhanced chemiluminescence (Pierce, IL).
The detected bands were quantified using Image J v1.43 as
instructed in the software manual.
ChIP assay
Chromatin immunoprecipitaton was performed with ChIP-IT
kits (Active Motif, Carlsbad, CA). Briefly, cells were fixed and
chromatin sonicated to 0.3–2 kb with most at 0.8 kb. A negative
IgG provided in the kit was used as a negative control antibody.
Chromatin samples were immunoprecipitated using depicted
antibodies, RNA removed by addition of Rnase A and cross-links
removed by incubating at 65uC for 4 hours. Proteins were
removed by treating with proteinase K, and DNA purified and
subjected to realtime PCR detection.
Luciferase assay
p21 promoter activity assay was carried out using Dual
Luciferase Reporter System (Promega) according to the manufac-
turer’s protocol. Briefly, ten thousand cells were seeded in 24-well
plates and incubated at 37uC overnight. Each well was co-
transfected with 200 ng luciferase plasmids (pGL3-Basic as
control, p21 promoter with/out p53 binding sites) and 5 ng
pRL-TK plasmids (Promega) encoding Renilla (internal control to
assess transfection efficiency). After 24 hours, whole-cell lysates
were collected and measured using an Orion Microplate
Luminometer (Berthold Detection System). Transfections were
performed in triplicate and repeated three times to assure
reproducibility. All luciferase reads were normalized to corre-
sponding Renilla value. Relative luciferase activity was calculated
using the following formula: Relative luciferase levels=Luc-
promoter/Luc-pGL3 basic.
Subcutaneously xenografted tumor
Animal protocols were approved by the Cedars Sinai Institu-
tional Animal Care and Use Committee (protocol # 2603). 5- to
6-week-old female athymic mice were separated into two groups,
one for HCT116 WT and another for HCT116 PTTG1
2/2 cells.
Cells (0.1 ml Matrigel containing 1610
6 cells) were injected
subcutaneously into the lumbar area at left side to generate
tumors. Tumors were allowed to grow when the first tumor
reaching ,100 mm
3, at which time mice were further randomized
to 2 treatment groups, with 10 evaluable tumors in each group: (a)
control and (b) drug treated. Doxorubicin was administered iv
through the tail vein (10 mg/kg) at day 1 after grouping. Mice
were monitored daily for signs of toxicity and weighed twice
weekly. Tumor sizes were measured twice weekly by caliper
measurements using the following formula: tumor volume=
(length6width
2) /2 as previously reported [30,31]. Relative tumor
growth was calculated by relative tumor size of treated mice
divided by relative tumor size of control mice (T/C). At the end of
the study, 3 weeks after cell injection, animals were euthanized
under CO2 inhalation followed by cervical dislocation to ensure
death (consistent with the Panel on Euthanasia of the American
Veterinary Medical Association). Tumor tissue was collected,
weighed and cut into three pieces for analysis. One was used for
mRNA extraction, one was frozen immediately in liquid nitrogen
for protein analysis and the third one fixed with formaldehyde,
embedded in paraffin and sectioned.
Immunofluorescence
Tissue sections were deparaffinized in xylene, hydrated in
graded ethanol, and heated in Target Retrieval Solution
(DakoCytomation) to retrieve antigen at 95uC for 40 minutes.
Slides were permeabilized with 1% triton-X-100 in PBS for 30
minutes, and incubated in blocking buffer (10% goat serum, 1%
BSA, 0.1% triton-X-100 in PBS) for 1 hour. After washing with
PBS, slides were hybridized at 4uC overnight with antibodies
against indicated proteins. Primary antibody was omitted for
negative controls. Alexa Fluor anti-mouse antibody with green
fluorescence or anti-rabbit antibody with red fluorescence
(Molecular Probes, Carlsbad, CA) were used as secondary
antibodies and incubated at room temperature avoiding light for
1 hour. Slides were mounted with ProLong Gold Antifade
Reagent with DAPI (Invitrogen), and nuclei dyed by DAPI with
blue fluorescence. Senescence activity in tissue samples was
assessed by measuring p21 expression and b-gal activity. Ten
fields were randomly selected and cells counted. Senescent or
apoptotic rate was calculated for each field as positive cells/all
cells6100%.
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2/2 cells are more sensitive to doxorubicin (Dox). a) HCT116 WT and PTTG1
2/2 cells expressing an empty vector
(WT+EV and PTTG1
2/2 +EV), and PTTG1 re-introduced PTTG1
2/2 (PTTG1
2/2 +PTTG1) cells were plated in 96-well plates and DNA synthesis assessed
at different time points (time 0 represents 0 hours after cell plating); b) HCT116 WT and PTTG1
2/2 cells expressing an empty vector (WT+EV and
PTTG1
2/2 +EV), and PTTG1 re-introduced PTTG1
2/2 (PTTG1
2/2 +PTTG1) cells were plated in 96-well plates for 24 hours and treated with control
vehicle (C) or different doxorubicin doses for another 48 hours. DNA synthesis was assessed by measuring BrdU incorporation; c) HCT116 WT and
PTTG1
2/2 cells were plated for 24 hours and treated with control vehicle (C) or doxorubicin (0.02 uM) for another 48 hours, fixed, stained for b-gal
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All results were expressed as mean6SD. Two group compar-
ison was assessed by non-paired, two tail Student’s t-test. The
difference between multiple groups was assessed by ANOVA.
Results
HCT116 PTTG1
2/2 cells exhibit enhanced drug-induced
senescence
We evaluated WT HCT116 and PTTG1
2/2 cell proliferation
by measuring BrdU incorporation. As shown in Fig. 1a, with
similar cell numbers plated, HCT116 WT and PTTG1
2/2 cells
exhibited similar absorbance (OD 0.4) at 0 hour. After 48 hours,
HCT116 WT cells showed an absorbance of 1.8 and PTTG1
2/2
cells 1.3 (28% decrease compared to WT, figure S1), suggesting
that HCT116 PTTG1
2/2 cell number were less than WT.
Reintroduction of PTTG1 into HCT116 PTTG1
2/2 cells
(PTTG1
2/2 +PTTG1) increased cell number after 48 hours (see
figure S2 for transfection efficiency), and these cells exhibited an
OD value of 2.1 (1.6 fold increase compared to PTTG1
2/2
expressing an empty vector). We then evaluated doxorubicin-
treated HCT116 WT and PTTG1
2/2 cells. As shown in Fig. 1b,
doxorubicin (0.005 uM) inhibited BrdU incorporation by 8% in
WT cells (OD value reduced from 1.8 in control vehicle group to
1.7 in doxorubicin group, not significant), and 42% in PTTG1
2/2
cells (OD value reduced from 1.3 in control vehicle group to 0.8 in
doxorubicin group, p,0.001). Treatment with higher doses
(0.02 uM) of doxorubicin inhibited BrdU incorporation by 52%
in WT cells and 85% in PTTG1
2/2 cells (p,0.05). As lower doses
(,0.1 uM) of doxorubicin cause senescence [32], and HCT116
PTTG1
2/2 cells were more sensitive to low dose doxorubicin as
measured by BrdU incorporation, we reasoned that HCT116
PTTG1
2/2 cells may undergo enhanced drug-induced senes-
cence. We therefore performed b-galactosidase (b–Gal) staining as
a marker to evaluate cell senescence. As indicated in Fig. 1c, few
cells stained positively when treated with control vehicle. After
doxorubicin (0.005 uM) treatment, 56% of HCT116 PTTG1
2/2
cells exhibited enhanced b–Gal staining, compared to 5% of WT
cells. We then tested whether apoptosis was involved in regulating
HCT116 PTTG1
2/2cells response to doxorubicin. HCT116 WT
and PTTG1
2/2 cells were Tunel assay positive only when treated
with higher doxorubicin doses (1.25 uM, Fig. 1d). Cleaved caspase
3 was not detected in doxorubicin (0.005–0.02 uM) treated
HCT116 WT cells even after 96 hours treatment (data not
shown). Thus enhanced PTTG1
2/2 cell sensitivity to low
doxorubicin doses is likely due to enhanced senescence rather
than apoptosis. We detected ,51% increase of doxorubicin-
induced senescence, but only ,30% decrease in cell numbers
when treated with 0.02 uM doxorubicin. This result might be due
to the fact that senescent cells are still metabolically viable.
Over-expressing PTTG1 attenuates drug-induced
senescence
To assess whether enhanced senescence and cell sensitivity
could be rescued, we reintroduced PTTG1 into HCT116
PTTG1
2/2 cells, and observed modest inhibition of BrdU
incorporation as compared to HCT116 PTTG1
2/2 cells (42%,
OD value reduced from 1.3 to 0.75) when treated with 0.005 uM
doxorubicin (p,0.001) (Fig. 1b). b–Gal staining indicated fewer
senescent cells when PTTG1 was re-introduced (6%) than in
control HCT116 PTTG1
2/2 cells (56%, p,0.001, Fig. 1c).
Trichostatin A (TSA) selectively inhibits histone deacetylase
(HDAC) enzymes [33], interfering with removal of histone acetyl
groups thereby altering transcription factor access to DNA. As
TSA induces senescence in several cell lines without causing DNA
damage [34,35], we tested whether HCT116 PTTG1
2/2 cells are
more sensitive to TSA. As shown in Fig. 2a, treatment with
0.3 nM TSA inhibited BrdU incorporation by 52% (OD value
reduced from 1.1 to 0.53) in HCT116 PTTG1
2/2 cells and 10%
(OD value reduced from 1.5 to 1.35) in WT cells (p,0.001). b-gal
staining showed that 75% of treated HCT116 PTTG1
2/2 cells
were senescent compared to 5% of treated WT cells (p,0.001,
Fig. 2b). When PTTG1 was reintroduced to PTTG1
2/2 cells, the
BrdU incorporation inhibition by TSA was decreased to 6%
(p,0.001 compared to 52% in PTTG1
2/2 cells, Fig. 2a). The
induction of senescence was decreased to 6% (p,0.001 compared
to 75% in PTTG1
2/2 cells, Fig. 2b), suggesting that PTTG1
attenuates the cell response to TSA treatment.
We then tested whether PTTG1 attenuates drug responsiveness
and drug-induced senescence in other cell types. SW620 colon
cancer cells transfected with empty vector or PTTG1 plasmids or
PTTG1 siRNA were treated with doxorubicin. In control vehicle
treated cells, PTTG1 knock down cells (PTTG1-knock down)
exhibited lower OD value (1.2) than WT (1.6, p,0.05 vs PTTG1-
knock down) and PTTG1 transfected cells (1.6, p,0.05 vs
PTTG1-knock down), suggesting that knock down of PTTG1
inhibited SW620 cell proliferation (Fig. 2c). After treatment with
doxorubicin (0.005 uM), BrdU incorporation was inhibited by
62% (OD value reduced from 1.2 to 0.46, p,0.001), compared to
12% (OD value was reduced from 1.6 to 1.4) in WT cells.
Senescence was enhanced in PTTG1-knock down cells (35%,
p,0.05, Fig. 2d). SW620 cells transfected with PTTG1 exhibited
inhibition of BrdU incorporation of 6% (OD value reduced from
1.8 to 1.69). In control (control vehicle-treated) group, few cells
appeared senescent. These results indicate that PTTG1 attenuates
SW620 colon cancer cell senescence and responsiveness to
doxorubicin.
p21 and drug-induced HCT116 PTTG1
2/2 cell
senescence
Doxorubicin-induced senescence is likely due to histone
acetylation induced p21 elevation rather than DNA damage
[35]. We evaluated the relative contribution of these two
mechanisms to our observations. Consistent with previous reports
[35], cells treated with low dose doxorubicin or TSA did not
exhibit H2AX phosphorylation (data not shown), suggesting that
DNA damage is not directly involved in drug-induced senescence.
Chromatin acetylation facilitates access of transcriptional machin-
ery to gene promoter regions [36], and we observed higher basal
and treatment-induced acetylated histone H3 and H4 levels
measured by western blot in HCT116 PTTG1
2/2 cells (Fig. 3a).
To test the requirement of p21 for enhanced senescence observed
in PTTG1
2/2 cells, we knocked down p21 and then assessed
effects of cell treatments. PTTG1
2/2 HCT116 cells exhibited
21% senescent cells when p21 was suppressed, compared to 58%
in control siRNA treated cells (p,0.001) (Fig 3 b), indicating the
requirement for p21 in PTTG1 mediated senescence. More-
over, HCT116 PTTG1
2/2 cells possess higher p21 levels. Over
activity and cells counted; d) HCT116 WT and PTTG1
2/2 cells were plated for 24 hours and treated with control vehicle (C) or different doses of
doxorubicin for another 48 hours, Tunel assay performed and positive cells counted. Each experiment was repeated three times. Results expressed as
mean6SD, n=3, *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0023754.g001
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SW620 cells (Fig 3 c).
Sp1 and p53 regulate p21 expression and senescence in
PTTG1
2/2 cells
Sp1 and p53 regulate p21 transcription [37], while PTTG1
enhances in vitro Sp1 binding [9] and also inhibits p53
transactivating activity [16]. We therefore evaluated p53 and
Sp1 protein levels and show that HCT116 PTTG1
2/2 cells
contain similar levels of p53 and Sp1 compared to WT cells
(Fig. 3d). After treated with 0.08, 0.313, 1.25, 5 uM of
doxorubicin, Sp1 levels did not change. p53 was only induced in
cells treated with 1.25 and 5 uM doxorubicin (Fig. 3d). Knock-
down of p53 reduced p21 levels in HCT116 WT and PTTG1
2/2
cells, and the number of cells exhibiting senescence were reduced
from 58% to 27% with TSA treatment as assessed by b–Gal
staining (Fig. 3b). Knockdown of Sp1 had a similar effect, with cell
senescence observed in 25% of cells. Sp1 and p53 protein levels
did not differ after treatment with 0.005–0.02 uM doxorubicin or
TSA (Fig. 3d), suggesting that p21 up-regulation is not associated
with Sp1 or p53 level changes. We then evaluated the Sp1 or p53
binding on p21 promoter. p21 promoter contains several Sp1 and
p53 binding sites (Fig. 4a). We designed 2 primer pairs spanning
22500,+50 bp of the p21 promoter (Fig. 4a), with primer pair 1
for p53 and primer pair 2 for Sp1 binding evaluation. The
difference in p53 binding between doxorubicin-treated WT and
PTTG1
2/2 cells was small (1.7 vs 2.4 fold, Fig. 4b). p53 binding
was enhanced ,3.4 fold in PTTG1
2/2 cells when treated with
TSA. Sp1 binding to the p21 promoter in WT but not PTTG1
2/2
cells was enhanced ,6.1 fold (p,0.001) by doxorubicin (Fig. 4c).
TSA enhanced Sp1 binding to the p21 promoter by ,6.7 fold
(p,0.001, Fig. 4c).
As Sp1 binding motifs are essential for p21 promoter activity
[38], we assessed the effects of deleting two p53 binding sites on
the p21 promoter. After transfection of pGL-basic plasmid
containing different p21 promoter fragments, those treated
transfectants containing two intact p53 binding motifs demon-
strated 2-fold higher activity in HCT116 PTTG1
2/2 than in WT
cells (Fig. 4d). Promoter constructs devoid of p53 binding motifs
showed similar activity in the two cell lines, suggesting that p53 is
required to regulate pGL-p21 promoter activity in both WT and
PTTG1
2/2 cells. However, when we treated WT and PTTG1
2/2
HCT116 cells with 0.005 uM doxorubicin or TSA, neither showed
enhanced pGL-p21 luciferase activity (Fig. 4d), suggesting that
chromatin changes may be involved.
Histone acetylation on the p21 promoter
As histone acetylation exposes chromatin to enable protein
binding to gene promoters, anti-acetylated histone H3 and anti-
acetylated histone H4 were used to co-immunoprecipitate
chromatin, and immunoprecipitated DNAs were evaluated using
primers targeting the p21 promoter. Both primer pairs detected
abundant enriched p21 promoters in HCT116 PTTG1
2/2 cells
when co-immunoprecipitated with acetylated histone H3 (Fig. 5a)
or H4 antibody (Fig. 5b). Primer 1 demonstrated ,2-fold
enhanced acetylated histone H3 in HCT116 PTTG1
2/2 cells.
Doxorubicin treatment resulted in 4.3-fold increase in WT and
6.2-fold increase in HCT116 PTTG1
2/2 cells (p,0.05), while
TSA treatment resulted in 6-fold increased acetylated histone H3
in WT, and ,10-fold increase in PTTG1
2/2 cells (p,0.05).
Primer 2 demonstrated a similar pattern (data not shown). We also
used a pair of negative primers (forward: ATGGTTGCCACTG-
GGGATCT; reverse: TGCCAAAGCCTAGGGGAAGA) that
flank genomic DNA between the GAPDH gene and the chro-
mosome condensation-related SMC-associated protein (CNAP1)
gene. As these negative primers did not detect differences between
HCT116 WT and PTTG1
2/2 cells before and after drug treat-
ment, it is likely that enhanced histone acetylation levels observed
in PTTG1
2/2 cells are specific for these specific regions including
the p21 promoter.
Histone acetylation levels are controlled by histone acetylation
transferase (HAT) and histone deacetylase (HDAC) [33]. To test
for global changes in HAT/HDAC activities, we measured HAT
and HDAC activity in vitro, and showed no difference in WT and
PTTG1
2/2 cells (data not shown). HAT accumulation or HDAC
decrease on these promoters might therefore lead to elevated
histone acetylation. P300, an E1A associated protein with
properties of a transcriptional adapter contains intrinsic histone
acetyl-transferase activity [39] and interacts with p53 and sp1 to
induce histone acetylation at corresponding regions [39,40]. We
therefore surveyed p300 binding on the p21 promoter using
primer pair 1 (Fig. 5c), and show that in PTTG1
2/2 cells p300
binding is 1.7-fold higher than in WT cells. After doxorubicin
treatment, p300 binding on the p21 promoter was increased 2.5-
and 6.6-fold in WT and PTTG1
2/2 cells respectively. Cells
treated with TSA demonstrated a similar enhancement of p300
binding. As HDAC-1 decreases histone acetylation levels and acts
as a co-repressor with p53 and sp1 [41], enhanced histone
acetylation in the p21 promoter may be due to decreased HDAC-
1 binding. After doxorubicin treatment, HDAC-1 binding
increased in PTTG1
2/2 cells (from 0.35 to 0.9 fold, Fig. 5d),
likely indicating a compensation for enhanced histone acetylation
in the p21 promoter. HDAC-1 binding to the p21 promoter was
not altered in TSA-treated HCT116 PTTG1
2/2 cells. Similar
changes were found by using primer pair 2 (data not shown).
To assess the involvement of p300 in regulating p21 promoter
activity, we knocked down p300 using siRNA and evaluated p21
promoter activity through a luciferase reporter assay. As shown in
Fig. 5e, knock down of p300 reduced the 3kb p21 promoter
activity by ,52% in PTTG1
2/2 HCT116 cells. To evaluate role
of p53 in p300 mediated p21 regulation, we used the p21
promoter devoid of the p53 binding site (p21-luc Dp53). P300
knock down reduced p21-luc Dp53 activity by 51% (Fig. 5e),
suggesting that regulatory effects of p300 on the p21 promoter
may occur independently of p53. p21-luc and p21-luc Dp53
exhibited a similar activity in HCT116 p53
2/2 cells, further
Figure 2. HCT116 PTTG1
2/2 and SW620 PTTG1 knock down (PTTG1-kd) cells exhibit enhanced drug-induced senescence. a) HCT116
WT, PTTG1
2/2 and PTTG1 re-introduced PTTG1
2/2 (PTTG1
2/2 +PTTG1) cells were plated in 96-well plates for 24 hours and treated with control
vehicle (C) or TSA for another 48 hours. DNA synthesis was assessed by measuring BrdU incorporation; b) HCT116 WT and PTTG1
2/2 cells were plated
for 24 hours and treated with control vehicle (C) or TSA (0.005 uM) for another 48 hours, fixed, stained for b-gal activity and cell number counted; c)
SW620 WT, PTTG1 knock down (PTTG1-kd) cells and PTTG1-transfected (PTTG1-tf) cells were plated in 96-well plates for 24 hours and treated with
control vehicle (C) or doxorubicin (Dox) for another 48 hours, DNA synthesis was assessed by measuring BrdU incorporation; d) SW620 WT, PTTG1
knock down (PTTG1-kd) cells and PTTG1 transfected (PTTG1-tf) cells were plated in 24-well plates for 24 hours, treated with control vehicle (C) or
doxorubicin (0.02 uM) for another 48 hours, b-gal staining performed and positive cells counted. Each experiment was repeated three times. Results
are expressed as mean6SD, n=3, *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0023754.g002
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23754Figure 3. PTTG1 down regulates p21 in colon cancer cells. a) HCT116 WT and PTTG1
2/2 cells were treated with control vehicle (C),
doxorubicin (Dox, 0.02 uM) or TSA (0.005 uM), and proteins analyzed by Western blotting to assess histone H3 and H4 acetylation; b) PTTG1
2/2 cells
were transfected with scrambled siRNA (C), or siRNA targeting p21, p53 or Sp1 respectively and treated with doxorubicin (0.02 uM) for 48 hours.
Protein levels were evaluated by Western blotting and senescence evaluated with b-gal staining; c) HCT116 or SW620 cells were transfected with
empty vector or scrambled siRNA (C) or PTTG1 plasmids or siRNA as indicated, proteins were extracted and PTTG1 and p21 levels evaluated by
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2/2 cells were treated with control vehicle (C) or different doses of doxorubicin (0.005, 0.05, 0.5 and 5 uM) for
48 hours Sp1 and p53 levels analyzed by Western blotting. Each experiment was repeated three times. Results are expressed as mean6SD, n=3,
*p,0.05, **p,0.001.
doi:10.1371/journal.pone.0023754.g003
Figure 4. Sp1 and p53 regulate p21 levels and promoter activities in HCT116 WT and PTTG1
2/2 cells. a) Primer pair 1 was designed to
detect protein binding close to p53 motifs on p21 promoter. Primer pair 2 was used to detect protein binding close to Sp1 binding site on p21
promoter; b) WT and PTTG1
2/2 cells treated with control vehicle (C), doxorubicin (Dox, 0.02 uM) or TSA (0.005 uM) for 48 hours and chromatin
immunoprecipitation performed using p53 antibody. Enriched chromatin was analyzed by qPCR using primer pair 1; c) WT and PTTG1
2/2 cells were
treated with control vehicle (C), Dox (0.02 uM) or TSA (0.005 uM) for 48 hours and chromatin immunoprecipitation performed using Sp1 antibody.
Enriched chromatins were analyzed by qPCR using primer pair 2; d) luciferase plasmids containing p21 promoters (with/out p53 binding motifs) were
transfected into drug-treated HCT116 WT and PTTG1
2/2 cells. Cells were harvested and luciferase activity analyzed. Each experiment was repeated
three times. Results are expressed as mean6SD, n=3, *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0023754.g004
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23754Figure 5. Protein levels on p21 promoter after drug treatment. a) WT and PTTG1
2/2 cells were treated with control vehicle (C), 0.02 uM
doxorubicin (Dox) or 0.005 uM TSA for 48 hours. Cells were harvested and chromatin immunoprecipitations performed using the indicated
antibodies. Enriched chromatins were evaluated using qPCR and primer pair 1. Levels of p21 promoter binding were normalized to these of WT
control HCT116 cells after doxorubicin or TSA treatment and are depicted as a) histone H3 acetylation; b) histone H4 acetylation; c) P300 binding; d)
HDAC1 binding; e) PTTG1
2/2 or p53
2/2 cells were transfected with scramble (C) or p300 siRNA, and p21 promoter containing or devoid of the p53
binding site. Results are expressed as mean6SD, n=3, *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0023754.g005
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2/2 tumors are more sensitive to doxorubicin (Dox). a) HCT116 WT and PTTG1
2/2 HCT116 cells were
implanted subcutaneously into nude mice and treated with control vehicle (C) or doxorubicin. Tumor dimensions were measured twice a week; b)
twenty one days after tumor cell xenografts, mice were sacrificed, tumors separated and weighed; c) harvested tumor tissues were sectioned and
stained with b-gal; d) tumor tissue was stained for p21 immunoreactivity; e) harvested tumor tissues were homogenized and Western blot performed.
Results are expressed as mean6SD, n=10, *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0023754.g006
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of p53.
In vivo studies
To test whether PTTG1-mediated senescence regulates tumor
development and anti-neoplastic drug responses in vivo,w e
evaluated HCT116 WT and PTTG1
2/2 cells using subcutaneous
xenografted tumors. As shown in Fig. 6a, volumes differed in WT
and PTTG1
2/2 tumors, starting from day 7 (12376493 vs
5016232 mm
3,p ,0.05). On day 19, the average volume of
control vehicle-treated WT tumors was 25596797 mm
3, doxoru-
bicin treated WT tumor was 20996529 mm
3 (18% inhibition
compared to control vehicle -treated WT tumors), control vehicle
-treated PTTG1
2/2 tumors was 14166585 mm
3 and doxorubi-
cin treated PTTG1
2/2 tumors was 3296263 mm
3, indicating a
77% inhibition (p,0.001) when compared to control vehicle-
treated PTTG1
2/2 tumors. Twenty one days after tumor cell
implantation, mice were sacrificed, tumors harvested and weighed.
PTTG1
2/2 tumors were smaller than WT (1.3260.39 vs
0.5260.18 g, p,0.001) (Fig. 6b), confirming results of the tumor
volume measurements. In doxorubicin treated groups, WT tumor
weight was reduced to 0.9960.29 (25% inhibition), PTTG1
2/2
tumor weight was reduced to 0.160.02 g (80% inhibition,
p,0.001). Body weights of control and treated mice were not
different (data not shown), suggesting limited serious drug toxic
effects.
Tumor tissues frozen in liquid nitrogen were sectioned and
stained. As subcutaneous xenografted tumors exhibited internal
necrosis (data not shown), only peripheral tumor tissue was used
for subsequent analysis. In WT subcutaneous tumors, 4% tumor
cells were senescent in control vehicle-treated, compared to 7% in
doxorubicin-treated group. In cells derived from excised
PTTG1
2/2 subcutaneous tumors, 36% exhibited enhanced b-
gal staining after doxorubicin treatment, compared to 10% in the
control vehicle treated group (Fig. 6c). The number of p21 positive
cells was increased in doxorubicin-treated PTTG1
2/2 tumors
(Fig. 6d). Western blotting of tumor tissue extracts showed
enhanced p21 levels in PTTG1
2/2 xenografted tumors, confirm-
ing the b-gal staining results (Fig. 6e).
Discussion
In this study, we demonstrate that HCT116 PTTG1
2/2 cells
display enhanced sensitivity to both doxorubicin and TSA.
Apoptosis, mitosis catastrophe or DNA damage were not detected,
but features of senescence were observed using low doses of
doxorubicin and TSA, suggesting that the PTTG1 mediated
response might be due to senescence. Reintroduction of PTTG1
into HCT116 PTTG1
2/2 cells reversed the enhanced sensitivity
and features of cell senescence, suggesting that the PTTG1 effect is
specific. We also evaluated PTTG1 functions in SW620 cells.
Knock down PTTG1 enhanced drug-induced senescence, con-
firming that PTTG1 functions to suppress drug-induced senes-
cence.
Senescence is a tumor suppressive program. It restrains cell
division, and is induced by age-linked telomere shortening,
oncogene activation, DNA damage, oxidative stress or chemo-
therapy [42,43]. Several lines of evidence indicate that senescence
contributes to cancer cell response to treatment. Senescence is
important for in situ radio-sensitization of human prostate
cancer cells [44], and mice bearing tumors developing drug-
induced senescence have enhanced prognosis following chemo-
therapy as compared to those harboring tumors with defective
senescence mechanisms [45]. The clinical doses of doxorubicin
(0.13 to 1.5 nmol/g) [46] were found to cause senescence in vitro
[32], suggesting a role for senescence in regulating doxorubicin
efficacy.
In addition to senescence, other mechanisms have been
proposed for PTTG1 regulation of drug sensitivity. PTTG1
interacts with p53 to inhibit cancer cell apoptosis [16], and with
the Ku heterodimer to inhibit DNA damage repair [47]. Cells
devoid of PTTG1 demonstrated impaired non-homologous DNA
end-joining and therefore may regulate cell responses to DNA
damage-inducing agents [48]. However, we did not detect DNA
damage caused by doxorubicin or TSA when treated with
indicated doses, which are in consistence with previously reported
[35].
As previous research in our laboratory showed p21 plays a key
role in regulating senescence [20,27,49], we focused our research
on investigating roles of PTTG1-p21 in drug-induced senescence.
Low doxorubicin concentrations (0.005–0.02 uM) induced histone
acetylation and promoted p21 expression, likely responsible for
enhanced cell senescence. In HCT116 PTTG1
2/2 cells, knock
down of p21 levels reduced the number of senescent cells,
suggesting that p21 is critical for the enhanced senescence
observed in HCT116 PTTG1
2/2 cancer cells. The specificity of
this pathway was confirmed using TSA, which also induces p21
and histone acetylation levels in treated cells. However, knock
down of p21 does not completely rescue features of enhanced
senescence, which could be either due to an incomplete knock
down or activation of other senescence pathways. The latter is
more likely because HCT116 colon cancer cells devoid of p21 are
senescent when treated with anti-cancer drugs [50].
Interestingly, although p21 levels are higher in HCT116
PTTG1
2/2 cells when treated with low dose doxorubicin and
TSA, the p21 promoter did not show enhanced activity under the
same treatments, suggesting that the p21 promoter luciferase assay
did not fully recapitulate the p21 transcription process. Our results
suggest higher levels of p53, Sp1, p300, acetylated histone H3 and
H4, and lower levels of HDAC1 on the p21 promoter in
PTTG1
2/2 cells. Both p53 and Sp1 recruit HDAC1 and p300 to
the promoter region [39]. PTTG1 binds p53 and Sp1 and
modulates their functions [9,16]. The results here showed more
abundant p53, Sp1 and p300 on the p21 promoter in HCT116
PTTG1
2/2 cells. Whether PTTG1 forms a transcription complex
with these factors on the p21 promoter requires further
investigation.
PTTG1 promotes tumor angiogenesis [24], but mechanisms
underlying PTTG1-mediated angiogenesis, cell death and drug
responses in vivo are unclear. As we observed enhanced drug-
induced senescence both in vitro and in vivo, we reasoned that
senescence may be a major cell arrest pathway involved. Although
clinical doses of doxorubicin cause senescence in vitro [32,46], the
true effect of low doses of doxorubicin requires further in vivo study.
In conclusion, these results demonstrate that PTTG1 regulates
drug-induced senescence, providing new insights for the role of
PTTG1 in determining cancer cell responses to anti-neoplastic
treatments.
Supporting Information
Figure S1 HCT116 PTTG1
2/2 cells are more sensitive to
doxorubicin (Dox). a) HCT116 WT and PTTG1
2/2 cells
expressing an empty vector (WT+EV and PTTG1
2/2 +EV),
and PTTG1 re-introduced PTTG1
2/2 (PTTG1
2/2 +PTTG1)
cells were plated in 96-well plates and DNA synthesis assessed at
different time points (time 0 represents 0 hours after cell plating);
b) HCT116 WT and PTTG1
2/2 cells expressing an empty vector
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2/2 +EV), and PTTG1 re-introduced
PTTG1
2/2 (PTTG1
2/2 +PTTG1) cells were plated in 96-well
plates for 24 hours and treated with control vehicle (C) or different
doxorubicin doses for another 48 hours. DNA synthesis was
assessed by measuring BrdU incorporation.
(TIF)
Figure S2 HCT116 cells were transfected with pEGFP-N1
plasmids and positive cells counted. Transfection efficiency was
calculated by using the formula: number of EGFP-positive cells/
Total cell number*100%.
(TIF)
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